Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Maraviroc in Hospitalized SARS-CoV-2
NCT04435522Phase 1Completed
- Sponsor
- Rhode Island Hospital
- Start
- Oct 2020
- Primary completion
- Dec 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of maraviroc in coronavirus disease 2019 (COVID-19), sponsored by Rhode Island Hospital. Primary endpoints: Rate of Completion at 7 days and Clinical Improvement at Day 7. Started Oct 2020; status: completed.
02
Drugs
maraviroc
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04435522.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04435522.